Evotec has initiated a “priority reset” to focus on profitable growth areas gaining momentum and building on core strengths.
 
The reset aims to achieve expected annualized adjusted EBITDA improvement of over €40 million starting in 2H24, through the exit of gene therapy and closing the site in Orth, Austria, and closure of Chemistry activities in Marcy (Lyon, France), the separation of manufacturing in Halle/Westphalia, Germany as non-core activity. Additionally, the company will reduce headcount from approximately 400 roles across the global footprint.
                   
As of July 1 2024, Dr. Christian Wojczewski took over as Chief Executive Officer from interim CEO Dr. Mario Polywka. Wesley Wheeler and Duncan McHale were elected to the Supervisory Board, replacing Dr. Elaine Sullivan and Dr. Mario Polywka.
 
Group revenues increased by 2% to € 390.8 million in the first half of 2024. Total shared R&D revenues decreased by 7% to €302.4 million, due to a challenging market environment. Meanwhile, Just – Evotec Biologics revenues increased by 50% to €88.5 million in the first half.